

ORIGINAL INVESTIGATION

Open Access

Gender disparities in diabetes and coronary heart disease medication among patients with type 2 diabetes: results from the DIANA study

Heike U Krämer^{1†}, Elke Raum^{1*†}, Gernot Rüter², Ben Schöttker¹, Dietrich Rothenbacher³, Thomas Rosemann⁴, Joachim Szecsenyi⁵ and Hermann Brenner¹

Abstract

Background: Coronary heart disease (CHD) is one of the most common long-term complications in people with type 2 diabetes. We analyzed whether or not gender differences exist in diabetes and CHD medication among people with type 2 diabetes.

Methods: The study was based on data from the baseline examination of the DIANA study, a prospective cohort study of 1,146 patients with type 2 diabetes conducted in South-West Germany. Information on diabetes and CHD medication was obtained from the physician questionnaires. Bivariate and multivariate analyses using logistic regression were employed in order to assess associations between gender and prescribed drug classes.

Results: In total, 624 men and 522 women with type 2 diabetes with a mean age of 67.2 and 69.7 years, respectively, were included in this analysis. Compared to women, men had more angiopathic risk factors, including smoking, alcohol consumption and worse glycemic control, and had more often a diagnosed CHD. Bivariate analyses showed higher prescription of thiazolidinediones and oral combination drugs as well as of angiotensin-converting enzyme (ACE) inhibitors, calcium channel blockers and aspirin in men than in women. After full adjustment, differences between men and women remained significant only for ACE inhibitors (OR = 1.44; 95%-confidence interval (CI): 1.11 – 1.88) and calcium channel blockers (OR = 1.42, 95%-CI: 1.05 – 1.91).

Conclusions: These findings contribute to current discussions on gender differences in diabetes care. Men with diabetes are significantly more likely to receive oral combination drugs, ACE inhibitors and calcium channel blockers in the presence of coronary heart disease, respectively. Our results suggest, that diabetic men might be more thoroughly treated compared to women. Further research is needed to focus on reasons for these differences mainly in treatment of cardiovascular diseases to improve quality of care.

Keywords: Medical management, Diabetes mellitus, Cardiology

Background

Type 2 diabetes mellitus (T2DM) is a major public health concern. It induces macro- and microvascular damage promoting long-term complications, like coronary heart disease (CHD), stroke or diabetic nephropathy, and is associated with significant morbidity and mortality [1,2]. The risk of CHD and stroke is altered by age,

gender, insulin and glycemic control in patients with diabetes mellitus [3], but gender-specific differences in the prevalence of cardiovascular diseases (CVD) might also decrease with rising age, especially in older women with diabetes compared to men of the same age [4].

Diabetes and CVD treatment is complex: besides the different applicable agents, disease status, comorbidities, self-management capabilities and individual compliance of patients have to be considered by the treating physicians [5,6]. Diabetes treatment is generally intensified if CVD risk factors or comorbidities, such as hypertension, hypercholesterolemia or CHD, are present and vice versa [7,8].

* Correspondence: e.raum@dkfz-heidelberg.de

†Equal contributors

¹Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Im Neuenheimer Feld 581, D-69120, Heidelberg, Germany
Full list of author information is available at the end of the article

However, there is evidence that women tend to receive a less adequate therapeutic management than men [9,10]. Until now, it is still unclear to what extent these gender differences can be explained by confounding factors, such as age, diabetes duration, adherence, prevalent depression or marital status [1,11].

We aimed to analyze whether or not gender disparities exist in diabetes and CHD medication after controlling for the most important confounding factors in an outpatient population of diabetic patients in Germany.

Methods

Study design and study population

This analysis is based on data from the baseline examination of the DIANA study (Type 2 Diabetes Mellitus: New Approaches to Optimize Medical Care in General Practice). DIANA is an epidemiological prospective cohort study with patients with T2DM conducted in the Ludwigsburg-Heilbronn area located in South-West Germany. The study was initiated in 2008 to address (short- and long-term) diabetes-related outcomes and to evaluate potentials for health care improvements in people with T2DM. People with a physician diagnosed T2DM aged 18 and older were recruited consecutively according to a standardized protocol by 38 general practitioners (GP) during regular practice visits between October 2008 and March 2010. The study protocol was approved by the Ethics Committees of the medical faculty of the University of Heidelberg and of the Chamber of Physicians of Baden-Württemberg.

Data collection

Participating patients completed a self-administered standardized questionnaire at baseline. Information related to diabetes and other medical conditions was reported by the attending physician through a standardized questionnaire. GPs reported all diabetes-relevant physician-diagnosed comorbidities ('yes'/'no') and submitted a complete list of all medications currently prescribed. Diabetes medication and CHD medication were classified according to the Anatomic Therapeutic Chemical (ATC) classification system (for more detailed information on classification see Additional file 1).

A blood sample was collected by the GP at time of recruitment and glycated haemoglobin A1c (HbA_{1c}) was assessed by a central laboratory, using ion exchange high pressure liquid chromatography (HPLC) (G8, Tosoh Biosciences).

Definition of key variables

For the following variables information from the GP questionnaire was used and they were defined accordingly: body mass index (BMI) in kg/m², most recent high density lipoprotein level (HDL) in mg/dl and blood

pressure (systolic/ diastolic) in mmHg, duration of diabetes and participation in a disease management program for T2DM (DMP-DM). CHD was defined as prevalent CHD or past myocardial infarction. Antidiabetic drugs were differentiated in biguanide, sulfonylurea, alpha-glucosidase inhibitor, thiazolidinedione, glinide, glucagon-like peptide-I (GLP-I) analogue exenatide, dipeptidyl peptidase-4 (DPP-4) inhibitor, oral combination drug (counted as one drug) and insulin treatment in general. Insulins were further specified in short acting human insulin, intermediate acting insulin (basal insulin), (human) insulin combination (short and intermediate acting) and insulin analogue. CHD medication was differentiated in antihypertensive drug, i.e. angiotensin-converting enzyme (ACE) inhibitor, diuretic, beta-blocker, calcium channel blocker and other hypertensive drug, such as angiotensin II receptor blocker, lipid lowering medication and aspirin (see Additional file 1).

The following information was obtained from the participant questionnaires: age at time of recruitment, gender, level of school education, marital status, occupational status, smoking history and alcohol consumption as well as number of appointments with the GP. Information on participants' self-estimated adherence to all prescribed medications was obtained by the 4-item self-report Morisky medication adherence questionnaire developed [12]. The sum score was calculated ranging from 0 (full adherence) to 4 (poor adherence). Patients were grouped as having a good (zero points), moderate (1 to 2 points) or poor adherence (3 to 4 points). The general health status was evaluated by the first question of the short-form-12 (SF-12) questionnaire [13].

Classification of glycemic control level was based on baseline HbA_{1c}, defining $\leq 6.4\%$ as good, 6.5% - 7.4% as moderate and $\geq 7.5\%$ as poor [14].

Statistical analysis

When information from the GPs' was not available (only 3.8% of the participants), information from the participants' questionnaires was used to minimize missing values, since we found very good agreement of both sources for participants for whom the information of both questionnaires was available (kappa coefficients for medications: >0.90 and for comorbidities: >0.80).

Descriptive statistics included 2-tailed t-tests for means and χ^2 -tests for proportions comparing differences between men and women. Analyzed covariates were socio-demographic characteristics, glycemic control, smoking status, alcohol consumption, diabetes duration, participation in a DMP-DM and comorbidities. Analyses on prescribed diabetes medication were stratified for gender and differentiated between the presence and absence CHD. Analyses on prescribed CHD medication were stratified for gender and restricted to participants with prevalent

CHD. Logistic regression was employed to estimate unadjusted and adjusted odds ratios (ORs) and corresponding 95% confidence intervals (95%-CIs) for describing the association between gender and use of diabetes or CHD medication. In order to adjust for the main independent determinants, variables for multivariate logistic regression models were selected by backward selection separately for each medication group (diabetes and CHD medications). Variables with a p-value < 0.1 were kept in the model to limit potential confounding. Statistical testing was two-sided, an alpha level of 5% was applied, and SAS 9.2 (SAS Institute, Cary, N.C., USA) was used throughout.

Results

Overall, 624 men (54.4%) and 522 women (45.6%) participated in this study (Table 1). On average, men were younger than women. Gender-specific differences also were found for other socio-demographic factors: women had a lower educational level, were more often singles and less often still employed. Smoking and alcohol consumption was far more prevalent in men than in women. Tentatively, more men than women showed a $HbA_{1c} \geq 7.5\%$. Men had significantly lower mean HDL levels than women. No gender differences were found for mean systolic or diastolic blood pressure. The number of GP appointments did not differ significantly between women and men. Self-reported medication adherence and self-rated general health status were similar between women and men. Men had significantly more often physician-diagnosed CVD and diabetes-related comorbidities, including CHD, intermittent claudication, stroke and diabetic nephropathy, whereas women had significantly more often a diagnosed depression.

Characteristics of diabetes medication stratified for gender and prevalent coronary heart disease are described in Table 2. Significantly more men than women took at least one diabetes medication (men: 77.7% vs. women: 69.6%, $p = 0.01$). The most frequently prescribed diabetes drugs in men and women were biguanides, sulfonylureas and insulins. The prescription of more expensive diabetes drugs, such as GLP-I analogues, DPP-4 inhibitors and oral combination drugs, was rather low among our study participants. Statistically significant gender-specific differences were evident for thiazolidinediones ($p = 0.04$) and oral combination drugs ($p = 0.02$). Overall, prescription of insulin (insulin or insulin analogue) was almost equally frequent among men and women, but was far more common among patients with CHD than without. The number of diabetes medications was statistically significantly increasing with level of glycemic control in men and women (Figures 1 and 2).

Table 1 Description of the study population

Variables of interest	Men (n = 624)		Women (n = 522)		p-value
	n	%	n	%	
Age in years (mean, SD*)	67.2 (10.1)		69.7 (10.5)		
Age in years					
≤59	137	22.0	84	16.1	
60 - 69	193	30.9	129	24.7	
70 - 79	239	38.3	231	44.3	
≥80	55	8.8	78	14.9	0.0001
Years of school education					
≤9	433	70.9	395	76.9	
10 - 12	104	17.0	94	18.2	
≥13	74	12.1	25	4.9	0.0001
Marital status					
Single/ widowed/ divorced	112	18.1	209	40.2	
Married	508	81.9	311	59.8	<0.0001
Occupational status					
Employed	158	26.5	78	15.7	
Retired	403	67.5	318	63.9	
Housewife	0	0	80	16.1	
Other	36	6.0	22	4.4	<0.0001
Smoking history					
Never	174	28.0	375	72.0	
Ex-smoker	355	57.2	100	19.2	
Current smoker	92	14.8	46	8.8	<0.0001
Alcohol consumption					
Abstainer	139	22.3	283	54.2	<0.0001
Body mass index (kg/m²)					
<25	76	12.2	78	14.9	
25 - <30	255	40.9	187	35.8	
30 - <35	194	31.1	161	30.8	
≥35	98	15.8	96	18.4	0.19
Glycemic control by HbA_{1c}					
Good (≤6.4%)	241	38.6	213	41.1	
Moderate (6.5 - 7.4%)	239	38.3	212	40.9	
Poor (≥7.5%)	144	23.1	93	18.0	0.10
Mean HbA_{1c} (SD) in %	6.9 (1.1)		6.8 (1.0)		0.14
Mean HDL (SD) in mg/dl	47.7 (14.3)		57.3 (17.2)		<0.0001
Mean systolic BP (SD) in mmHg	137.8 (18.1)		136.8 (19.0)		0.41
Mean diastolic BP (SD) in mmHg	79.4 (10.2)		79.6 (10.5)		0.68
Physician reported time since diabetes diagnosis					
≤5 years	241	38.6	213	40.8	
6 - 10 years	185	29.7	146	28.0	
11 - 15 years	104	16.7	81	15.5	
≥16 years	94	15.1	82	15.7	0.82

Table 1 Description of the study population (Continued)

Appointments with GPs (last 3 months)					
≤1	260	41.7	197	37.9	
2 – 3	245	39.3	216	41.5	
≥4	119	19.1	107	20.6	0.43
Participation in a DMP-DM	471	79.4	398	81.7	0.34
Medication adherence					
Good	455	75.6	385	77.0	
Moderate	132	21.9	102	20.4	
Poor	15	2.5	13	2.6	0.83
General health status (self-rated)					
Excellent or very good	62	10.0	40	7.7	
Good	366	58.7	291	55.8	
Fair	174	27.9	172	32.9	
Poor	21	3.4	19	3.6	0.21
Physician diagnosed comorbidities					
Hypertension	488	78.3	407	78.1	0.93
Hypercholesterolemia	350	56.2	300	57.8	0.58
Coronary heart disease	147	23.6	67	12.8	<0.0001
Heart failure	75	12.0	64	12.3	0.89
Intermittent claudication	96	15.4	36	6.9	<0.0001
Stroke	47	7.5	22	4.2	0.02
Nephropathy	76	12.2	45	8.6	0.05
Retinopathy	51	8.2	35	6.7	0.35
Neuropathy	144	23.1	104	20.0	0.20
Depression	67	10.7	97	18.6	0.0002
Cancer	63	10.1	49	9.4	0.70

*SD = standard deviation; HbA_{1c} = glycated haemoglobin A1c; GP = general practitioner;
DMP-DM = disease management program for treatment of patients with type 2 diabetes.
Missing values: education: 21, marital status: 6, occupational status: 51, smoking: 4, BMI: 1, HbA_{1c}: 4, HDL: 270, systolic and diastolic BP: 70, appointments with GPs: 2, DMP-DM: 66, adherence: 44, health status: 1, hypertension: 2, hypercholesterolemia: 4, CHD: 2, heart failure: 1, intermittent claudication: 1, stroke: 2, nephropathy: 1, retinopathy: 1, depression: 1, cancer: 1
Significant results ($p < 0.05$) by χ^2 test are printed bold.

Table 3 shows the prevalence of CHD medication stratified by gender. Statistically significant gender-specific differences were found for ACE inhibitors ($p = 0.003$), calcium channel blockers ($p = 0.01$) and aspirin ($p = 0.002$). In the group of CHD patients, statistically significant gender-specific differences were only evident for ACE inhibitors ($p = 0.02$) and calcium channel blockers ($p = 0.004$).

The results of logistic regression analyses regarding the association between gender and diabetes and CHD medications with significant gender differences ($p < 0.05$) are described in Table 4. Men had 53% increased odds to receive any antidiabetic drug compared to women

(95%-CI: 1.17 – 1.99, no table). Men compared to women had 1.8 and 2.5 higher odds to receive thiazolidinediones and oral combination drugs. After stratification for CHD, no significant gender-specific difference in diabetes medication was seen. After full model adjustment men had still 44% and 42% increased odds to receive ACE inhibitors and calcium channel blockers. A positive association between male gender and antithrombotic therapy with aspirin was also observed. In participants with CHD, gender-specific prescription differences of ACE inhibitors and calcium channel blockers were particularly strong. Significant gender differences in ACE inhibitors in CHD patients with diabetes sustained after adjusting for age, HbA_{1c}, appointments with GP, medication adherence and comorbidities that are indications for renin-angiotensin system (RAS) blockade. Overall, all logistic regression models showed a very good model fit by Hosmer-Lemeshow test.

Discussion

Our results demonstrate that men with diabetes were significantly more likely to receive oral combination drugs, ACE inhibitors and calcium channel blockers for CHD than women. Gender-specific differences could also be observed for aspirin use for the overall study sample, but not for the CHD subsample. Taken together, these patterns suggest that diabetic men might be more thoroughly treated than women, especially in terms of CHD medication. Furthermore, the number of diabetes medication was significantly increasing with the level of glycemic control and diabetes duration in men and women with diabetes.

Our finding of gender-specific, also not statistically significant differences in the prescription of diabetes medication such as thiazolidinediones is in accordance with the results of a German cross-sectional study [15]: Lehnert et al. analyzed data on 6,786 people with diabetes in primary care and found a slightly higher prescription rate of thiazolidinediones in men (4.4%) than in women (3.6%) above the age of 60 years. Apart from the different time frames of the studies (Lehnert et al.: 2001; our study: 2008–2010), differences in prescription rates might be mainly explained by disparities in diabetes duration (Lehnert et al.: 4.5 (± 1.2 years) vs. our study: 8.8 (± 7.1 years)) which is one of the main determinants of treatment choice. Reasons for the higher prescription of thiazolidinediones in men than in women are unclear. Studies have suggested that thiazolidinediones have beneficial effects on inflammatory and atherogenic parameters, blood pressure and microalbuminuria [16] and that thiazolidinediones doubles the risk of fractures among women, but not among men with diabetes [17]. Due to severe side effects the most frequently prescribed thiazolidinediones, namely Rosiglitazone and Pioglitazone, can no

Table 2 Diabetes medication by gender and prevalent coronary heart disease

Medication of interest			With coronary heart disease				Without coronary heart disease					
	Men		Women		Men		Women		Men		Women	
	(n = 624)		(n = 522)		(n = 147)		(n = 67)		(n = 477)		(n = 455)	
	n	%	n	%	n	%	n	%	n	%	n	%
Number of diabetes medication (mean, STD*)	1.3 (1.1)		1.3 (1.2)		1.5 (1.3)		1.4 (1.1)		1.3 (1.1)		1.2 (1.2)	
Number of diabetes medication												
0	138	22.3	158	30.4	27	18.5	15	22.7	111	23.5	143	31.6
1	245	39.6	175	33.7	50	34.3	22	33.3	195	41.2	153	33.8
2	159	25.7	113	21.8	46	31.5	17	25.8	113	23.9	96	21.2
3 and more	77	12.4	73	14.1	23	15.7	12	18.2	54	11.4	61	13.5
Biguanide	343	55.0	273	52.3	70	47.6	35	52.2	273	57.2	238	52.3
Sulfonylurea	132	21.2	92	17.6	32	21.8	14	20.9	100	21.0	78	17.1
Alpha-glucosidase inhibitor	14	2.2	13	2.5	5	3.4	1	1.5	9	1.9	12	2.6
Thiazolidinedione	39	6.3	19	3.6	11	7.5	3	4.5	28	5.9	16	3.5
Glinide	21	3.4	13	2.5	6	4.1	1	1.5	15	3.1	12	2.6
Glucagon-like peptide-1 analogue (GLP-1) exenatide	6	1.0	5	1.0	4	2.7	0	0	2	0.4	5	1.1
Dipeptidyl peptidase-4 (DPP-4) inhibitor	20	3.2	28	5.4	7	3.3	4	6.0	17	3.6	24	5.3
Oral combination drug	26	4.2	9	1.7	6	4.1	1	1.5	20	4.2	8	1.8
Insulin treatment	123	19.8	107	20.5	43	29.7	20	29.8	80	16.8	87	19.1
Short acting insulin	47	7.5	40	7.7	16	10.9	7	10.4	31	6.5	33	7.3
Intermediate acting (basal insulin)	53	8.5	56	10.7	19	12.9	10	14.9	34	7.1	46	10.1
Human insulin combination (short and intermediate acting)	22	3.5	14	2.7	8	5.4	4	6.0	14	2.9	10	2.2
Insulin analogue	58	9.3	43	8.2	22	15.0	8	11.9	36	7.5	35	7.7

*SD = standard deviation. Number may not always add up to total because of missing values for some items. Significant results ($p < 0.05$) by χ^2 -test are printed bold.

longer be prescribed for diabetes treatment in Germany since April 2011 [18], and Rosiglitazone was recommended for suspension by the European Medicines Agency (EMA) in September 2010 [19].

The higher prescription rate of oral combination drugs in men compared to women with T2DM might be explained by the higher number of comorbidities and burden of disease in participating men compared to




Figure 1 Mean number (\pm standard error) of diabetes medication by glycemic control.




Figure 2 Mean number (\pm standard error) of diabetes medication by diabetes duration.

women and the attempt of the general practitioners to reduce the overall number of medication especially for men.

Our findings regarding CHD medication are in line with previous research: The results of the Euro Heart Survey on Heart Failure including 8,914 patients with heart failure showed that women got less ACE inhibitors and beta-blockers than men [20]. A German cross-sectional study on 1,857 consecutive patients with heart failure likewise showed a difference in the prescription of ACE inhibitors and dosage of beta-blockers, and revealed a less evidence-based treatment in women than in men [21]. For patients with diabetes mellitus, a Swedish study including 229 primary care centres revealed - similar to our study - that men were more often prescribed ACE inhibitors than women and that only one third of the patients below 75 years was on lipid-lowering drug therapy [22]. The higher prescription rate of ACE inhibitors among men can potentially be explained not only by the higher CVD comorbidity, but

also by the higher prevalence of nephropathy in men than in women and the protective effect of ACE inhibitors towards progression of nephropathy [23]. Brannström et al [24] investigated gender disparities in the pharmacological treatment of cardiovascular disease and diabetes mellitus in a cohort of elderly people aged 85 years or older. Women received significantly more drugs, more diuretics, more nitrates. In contrast to our study, no differences were found for insulin therapy, Aspirin and ACE inhibitors, but ACE inhibitor prescription rates were considerably lower in this study compared to ours. For patients with coronary events or revascularisation the EUROASPIRE III study found higher ACE-inhibitors prescription rates for men than for women. Women receive more diuretics, insulin and oral antidiabetic agents [25]. Lipid lowering treatment is generally recommended for all people with T2DM with a high risk for macroangiopathic complications or with CHD [26]. The underuse of lipid lowering drugs together with a lack of antithrombotic drugs might point to a

Table 3 Coronary heart disease medication by gender and prevalent coronary heart disease

Medication of interest	All		Women		With coronary heart disease			
	Men		Women		Men		Women	
	(n = 624)		(n = 522)		(n = 147)		(n = 67)	
	n	%	n	%	n	%	n	%
Antihypertensive drug	507	81.3	412	78.9	144	98.0	63	94.0
Angiotensin-converting enzyme (ACE) inhibitor	431	69.1	316	60.5	120	81.6	45	67.2
Diuretic	186	29.9	176	33.7	70	47.9	34	50.7
Beta-blocker	267	42.8	228	43.7	112	76.2	48	71.6
Calcium channel blocker	168	26.9	106	20.3	50	34.0	10	14.9
Lipid lowering drug	277	44.4	216	41.4	110	74.8	45	67.2
Aspirin	213	34.1	133	25.5	102	69.4	45	67.2

Number may not always add up to total because of missing values for some items. Significant results ($p < 0.05$) by χ^2 test are printed bold.

Table 4 Results of diabetes and coronary heart disease medication: Odds ratios (95% confidence intervals) for men compared to women (reference)

		Total	With coronary heart disease	Without coronary heart disease
Diabetes Medication				
Thiazolidinedione	Crude	1.77 (1.01 - 3.09)	1.73 (0.47 - 1.58)	1.71 (0.91 - 3.21)
	Adjusted ^a	1.75 (0.99 - 3.08)	1.58 (0.41 - 6.07)	1.68 (0.89 - 3.17)
	Adjusted ^b	1.42 (0.79 - 2.57) ¹	0.94 (0.28 - 3.17) ²	1.52 (0.81 - 2.85) ³
Oral combination drug	Crude	2.48 (1.51 - 5.34)	2.81 (0.33 - 23.79)	2.45 (1.07 - 5.61)
	Adjusted ^a	1.97 (0.94 - 4.13)	1.82 (0.21 - 15.96)	1.91 (0.82 - 4.45)
	Adjusted ^b	2.06 (0.98 - 4.31) ⁴	1.93 (0.38 - 9.78) ⁵	1.87 (0.84 - 4.13) ⁶
Coronary Heart Disease Medication				
Angiotensin-converting enzyme inhibitor	Crude	1.46 (1.14 - 1.86)	2.17 (1.12 - 4.20)	
	Adjusted ^a	1.52 (1.18 - 1.95)	2.18 (1.09 - 4.35)	
	Adjusted ^c	1.44 (1.11 - 1.88) ⁷	-	
	Adjusted ^d	-	2.61 (1.26 - 5.42) ⁸	
Calcium channel blocker	Crude	1.45 (1.10 - 1.91)	2.94 (1.38 - 6.24)	
	Adjusted ^a	1.55 (1.17 - 2.06)	3.53 (1.58 - 7.89)	
	Adjusted ^c	1.42 (1.05 - 1.91) ⁹	-	
	Adjusted ^d	-	3.64 (1.55 - 8.52) ¹⁰	
Aspirin	Crude	1.52 (1.17 - 1.96)	1.10 (0.58 - 2.08)	
	Adjusted ^a	1.80 (1.38 - 2.36)	0.96 (0.49 - 1.87)	
	Adjusted ^e	1.36 (1.01 - 1.84) ¹¹	-	
	Adjusted ^f	-	1.12 (0.57 - 2.21) ¹²	

Adjusted for: ^aage and HbA_{1c} level, ^bage, HbA_{1c} level, physician reported diabetes duration, appointments with the GP, marital status, diabetic nephropathy, depression, ^cage, HbA_{1c} level, appointments with the GP, medication adherence, coronary heart disease, stroke, intermittent claudication, diabetic nephropathy and depression, ^dage, HbA_{1c} level, appointments with the GP, medication adherence, stroke, intermittent claudication, diabetic nephropathy and depression, ^eage, HbA_{1c} level, appointments with the GP, medication adherence, coronary heart disease, stroke, diabetic nephropathy and depression, ^fage, HbA_{1c} level, appointments with the GP, medication adherence, stroke, diabetic nephropathy and depression.

Goodness of fit: ¹p = 0.74; ²p = 0.87; ³p = 0.33; ⁴p = 0.66; ⁵p = 0.85 ⁶p = 0.66; ⁷p = 0.83; ⁸p = 0.46; ⁹p = 0.93; ¹⁰p = 0.70; ¹¹p = 0.13; ¹²p = 0.76.

suboptimal quality of health care, because both are crucial for the reduction of cardiovascular comorbidity and all-cause mortality in people with diabetes [27-29]. A large Danish primary care study [30] on patients screened for diabetes with a high risk for CVD and a large US retrospective study [31] on people with diabetes found that less women than men received an adequate lipid-lowering treatment. In our study which was conducted between 2008 and 2010, already 43% of the patients with diabetes received lipid lowering drugs, but with no differences between men and women.

In summary, as various studies [32,33] and a recently published review [34] point out, gender differences regarding diabetes mellitus are present for all steps in the glucometabolic pathway starting with differences in patho-physiological disturbances, the risk factor distribution, incidence and prevalence of complications, and finally diagnostic techniques and therapy. Franconi et al conclude, that a gender specific approach for all aspects of patient care is much needed to improve overall perspective of patients with diabetes mellitus [34].

Our study results are limited by the cross-sectional study design, i.e. causality cannot be derived and no conclusion on trends in treatment can be drawn. In particular, our study did not allow identifying with certainty the potential reasons underlying gender differences in medication. The relatively small numbers in each medication group limited the power to detect differences of small and moderate size. Although we aimed for the inclusion of all people with T2DM in a large number of practices, selection effects of participating GPs and regional variation in treatment might limit generalizability. Furthermore, the insurance status was not recorded at baseline. We could not perform a detailed monitoring of completeness of recruitment of diabetes patients in the practices.

Conclusions

Men with diabetes were significantly more likely to receive oral combination drugs, ACE inhibitors and calcium channel blockers in the presence of coronary heart disease. These patterns suggest that diabetic men might be more thoroughly treated than women, especially in

terms of CHD medication. We hope that our results will contribute to and stimulate the discussion on gender-specific disparities in diabetes healthcare.

Additional file

Additional file 1: Anatomic Therapeutic Classification (ATC) code.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

HUK conducted the statistical analysis and HUK and ER drafted the manuscript. ER, GR, DR, TR, JS and HB designed the study, supervised its implementation and field activities. All contributing authors were revising the manuscript critically for important intellectual content. All authors have read and approved the final version of the manuscript.

Support

This study was supported by a grant of the Federal Ministry of Education and Research (study identification number: 01GX0746).

Acknowledgement

Conflict of interest statement: we declare that we have no conflict of interest. We wish to thank all the participants of the DIANA study and our cooperating study partners. This study was supported by a grant of the Federal Ministry of Education and Research (study identification number: 01GX0746) and is registered at ClinicalTrials.gov (identification number: NCT00742547). The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Author details

¹Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Im Neuenheimer Feld 581, D-69120, Heidelberg, Germany. ²Practice of General Medicine, Blumenstrasse 11, D-71726, Benningen/Neckar, Germany. ³Institute of Epidemiology and Medical Biometry, Ulm University, Helmholtzstr. 22, D-89081, Ulm, Germany. ⁴Department of General Practice and Health Services Research, University of Zürich, University Hospital of Zürich, Pestalozzistrasse 24, CH-8091, Zürich, Switzerland. ⁵Department of General Practice and Health Services Research, University Hospital Heidelberg, Vossstrasse 2, Geb. 37, D-69115, Heidelberg, Germany.

Received: 23 February 2012 Accepted: 12 July 2012

Published: 27 July 2012

References

1. Rivellese AA, Riccardi G, Vaccaro O: **Cardiovascular risk in women with diabetes.** *Nutr Metab Cardiovasc Dis* 2010, **20**:474–480.
2. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ: **Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data.** *Lancet* 2006, **367**:1747–1757.
3. Hayashi T, Kawashima S, Nomura H, Itoh H, Watanabe H, Ohrai T, Yokote K, Sone H, Hattori Y, Yoshizumi M, Ina K, Kubota K, the Japan Cholesterol and Diabetes Mellitus Investigation Group: **Age, gender, insulin and blood glucose control status alter the risk of ischemic heart disease and stroke among elderly diabetic patients.** *Cardiovasc Diabetol* 2011, **10**:86.
4. Mercurio G, Deidda M, Piras A, Dessalvi CC, Maffei S, Rosano GM: **Gender determinants of cardiovascular risk factors and diseases.** *J Cardiovasc Med* 2010, **11**:207–220.
5. Heisler M, Piette JD, Spencer M, Kieffer E, Vijan S: **The relationship between knowledge of recent HbA(1c) values and diabetes care understanding and self-management.** *Diabetes Care* 2005, **28**:816–822.
6. King DK, Glasgow RE, Toobert DJ, Strycker LA, Estabrooks PA, Osuna D, Faber AJ: **Self-efficacy, problem solving, and social-environmental support are associated with diabetes self-management behaviors.** *Diabetes Care* 2010, **33**:751–753.
7. American Diabetes Association (ADA): **Standards of medical care in diabetes - 2010.** *Diabetes Care* 2010, **33**(Suppl 1):11–61.
8. Tschöpe C, Schultheiss HP: **Diabetic cardiopathy: pathogenesis, diagnosis and therapy.** *Internist* 2003, **44**:806–818 [Article in German].
9. Ferrara A, Mangione CM, Kim C, Marrero DG, Curb D, Stevens M, Selby JV: **Translating Research Into Action for Diabetes Study Group. Sex disparities in control and treatment of modifiable cardiovascular disease risk factors among patients with diabetes: Translating Research Into Action for Diabetes (TRIAD) Study.** *Diabetes Care* 2008, **31**:69–74.
10. Gouni-Berthold I, Berthold HK, Mantzoros CS, Bohm M, Krone W: **Sex disparities in the treatment and control of cardiovascular risk factors in type 2 diabetes.** *Diabetes Care* 2008, **31**:1389–1391.
11. Roe CM, McNamara AM, Motheral BR: **Gender- and age-related prescription drug use patterns.** *Ann Pharmacother* 2002, **36**:30–39.
12. Morisky DE, Green LW, Levine DM: **Concurrent and predictive validity of a self-reported measure of medication adherence.** *Med Care* 1986, **24**: 67–74.
13. Ware J Jr, Kosinski M, Keller SD: **A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity.** *Med Care* 1996, **34**:220–233.
14. American Diabetes Association (ADA): **Executive summary: standards of medical care in diabetes - 2010.** *Diabetes Care* 2010, **33**(Suppl 1):4–10.
15. Lehnert H, Wittchen HU, Pittrow D, Bramlage P, Kirch W, Böhler S, Höfler M, Ritz E: **Prevalence and pharmacotherapy of diabetes mellitus in primary care.** *Dtsch Med Wochenschr* 2005, **130**:323–328 [Article in German].
16. Scherthaner G, Forst T, Gulba D, Haberbosch W, Hanefeld M, Linn S, März W, Mehnert H, Rosak C, Schnell O, Seufert J, Tschöpe D, Erdmann E: **Challenge in diabetes therapy: effects of glitazones beyond blood glucose control.** *Dtsch Med Wochenschr* 2009, **134**:949–954 [Article in German].
17. Loke YK, Singh S, Furberg CD: **Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis.** *CMAJ* 2009, **180**:32–39.
18. Gemeinsamer Bundesausschuss (GBA): **Arzneimittel-Richtlinie/ Anlage III (Glitazone zur Behandlung des Diabetes mellitus Type 2).** <http://www.g-ba.de/informationen/beschluesse/1141/>. 02 July 2012.
19. European Medicines Agency: **European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglin.** http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/general_content_000420.jsp&mid=WC0b01ac058001d126. 02 July 2012.
20. Lenzen MJ, Rosengren A, op Reimer WJ S, Follath F, Boersma E, Simoons ML, Cleland JG, Komajda M: **Management of patients with heart failure in clinical practice: differences between men and women.** *Heart* 2008, **94**:e10.
21. Baumhäkel M, Müller U, Böhm M: **Influence of gender of physicians and patients on guideline-recommended treatment of chronic heart failure in a cross-sectional study.** *Eur J Heart Fail* 2009, **11**:299–303.
22. Nilsson PM, Theobald H, Journath G, Fritz T: **Gender differences in risk factor control and treatment profile in diabetes: a study in 229 swedish primary health care centres.** *Scand J Prim Health Care* 2004, **22**:27–31.
23. Hasslacher C, Wolf G, Kempe P, Ritz E: **Diabetic Nephropathie.** *Diabetologie und Stoffwechsel* 2010, **5**(Suppl 2):S113–S116 [Article in German].
24. Brannström J, Hamberg K, Molander L, Lövhelm H, Gustafson Y: **Gender disparities in the pharmacological treatment of cardiovascular disease and diabetes mellitus in the very old.** *Drugs Aging* 2011, **28**:993–1005.
25. Dallongville J, De Bacquer D, Heidrich J, De Backer G, Prugger C, Kotseva K, Montaye M, Amouyel P: **Gender differences in the implementation of cardiovascular prevention measures after an acute coronary event.** *Heart* 2010, **96**:1744–1749.
26. Gaede P, Lund-Andersen H, Parving HH, Pedersen O: **Effect of a multifactorial intervention on mortality in type 2 diabetes.** *N Engl J Med* 2008, **358**:580–591.
27. Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C: **Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis.** *Lancet* 2008, **371**:117–125.
28. Wiggins TD, Sullivan KA, Pop-Busui R, Amato A, Sima AA, Feldman EL: **Elevated triglycerides correlate with progression of diabetic neuropathy.** *Diabetes* 2009, **58**:1634–1640.
29. Squizzato A, Keller T, Romualdi E, Middeldorp S: **Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease.** *Cochrane Database Syst Rev* 2011, CD005158.

30. Graversen L, Christensen B, Borch-Johnsen K, Lauritzen T, Sandbaek A: **General practitioners' adherence to guidelines on management of dyslipidaemia: ADDITION-Denmark.** *Scand J Prim Health Care* 2010, **28**: 47–54.
31. Fu AZ, Zhang Q, Davies MJ, Pentakota SR, Radican L, Seck T: **Underutilization of statins in patients with type 2 diabetes in US clinical practice: a retrospective cohort study.** *Curr Med Res Opin* 2011, **27**: 1035–1040.
32. Leosdottir M, Willenheimer R, Persson M, Nilsson PM: **The association between glucometabolic disturbances, traditional cardiovascular risk factors and self-rated health by age and gender: a cross-sectional analysis within the Malmö preventive project.** *Cardiovasc Diabetol* 2011, **10**:118.
33. Moebus S, Balijepalli C, Löscher C, Göres L, von Stritzky B, Bramlage P, Wasem J, Jöckel KH: **Age- and sex-specific prevalence and ten-year risk for cardiovascular disease of all 16 risk factors combinations of the metabolic syndrome –a cross-sectiona study.** *Cardiovasc Diabetol* 2010, **9**:34.
34. Franconi F, Campesi I, Occhioni S, Tonolo G: **Sex-gender differences in diabetes vascular complications and treatment.** *Endocr Metab Immune Disord Drug Targets* 2012, **12**:179–196.

doi:10.1186/1475-2840-11-88

Cite this article as: Krämer *et al.*: Gender disparities in diabetes and coronary heart disease medication among patients with type 2 diabetes: results from the DIANA study. *Cardiovascular Diabetology* 2012 **11**:88.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

